Epilepsy

FDA Grants Marketing Clearance for a New Treatment

Published in Medical Letter on the CDC and FDA, January 31st, 2000

Novartis Pharmaceuticals Corporation announced that the US Food and Drug Administration (FDA) has granted marketing clearance for Trileptal (oxcarbazepine) tablets.

Trileptal belongs to the class of drugs known as anticonvulsant or antiepileptic drugs (AEDs). The medication is indicated for the treatment of partial seizures as monotherapy in adults or adjunctive therapy (use in combination with other AEDs) in adults and children as young as 4 years of age.

"Currently, approximately 30-50% of people with epilepsy may continue to experience seizures despite treatment with the medications now available, and for those who are able to control their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry